Stockreport

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones [Yahoo! Finance]

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 SAN DIEGO, March 05, 2026 BUSINESS [Read more]